Sense of the life

 
AEQUILIBRIUM PHARMA
Biosimilar Solution and Pioneering Biomolecules
Aequilibrium pharma is a privately held biotech company, founded in 2018 in Milan,Italy. We are committed to finding treatments for severe diseases with large unmet clinical needs such as pain and aggressive metastatic cancer using our unique angle of a targeted functionality antibody approach.

Products

Asset-generation through  our game-changing antibody platform

A new beginning for effective targets that failed due to severe toxicity
In most cases, we select targets that have been clinically or genetically validated, often by small molecule approaches, that were highly effective but failed due to severe toxicity. We use our unique Plant platform, to develop novel therapeutic antibodies against these targets while maintaining efficacy but with a completely different and improved toxicity profile. We also run two programs to address disruptive but scientifically compelling targets.

Transient expression in plants is an effective method for the expression of proteins  





Aequilibrium Pharma production is designed to fill the gap between transient production and traditional stable pool methodologies. Compared to transient production, AEQ pharma Express delivers significantly more material, yet only adds 1 week to the overall timeline. AEQ pharma Express is ideal when you need over 500 mg of purified protein or antibody to be delivered as soon as possible. here next are some common applications for materials obtained from AEQuilibrium pharma Express production.


Aequilibrium Express technology changes the paradigm of recombinant-protein manufacture. Traditional production-scale processes rely on bacterial, yeast, or mammalian cell-culture expression systems, transgenic animals, or purification from natural sources. The limitations of these approaches include inadequate or non-sustainable supply from naturally occurring sources; low manufacturing yields with high capital-investment requirements and operating costs, and associated high cost of production; and potential for contamination from by-products present in the background organism or natural source.

Eukaryotic expression system: plants can manufacture complex biologics that are difficult to make in other hosts, including proteins requiring post-translational modification.
Flexibility: ability to manufacture multi-subunit molecules, monoclonal antibodies, fusion proteins, and enzymes.
Purity: products that are inherently free of animal, human, or microbial by-products, making them ideal for therapeutic use or for use in sensitive and exacting biotechnology applications.
Cost-effectiveness: suitable for cGMP manufacturing with dramatically lower cost of production.
Scalability: recombinant protein yields from kilograms to hundreds of metric tons.
Simplicity: batch-purification uses a simple, scalable, aqueous process with a 12 to 16-hour batch time.

Technology Approaches for Bispecific Antibody Development


As an undisputed global leader in antibody engineering and manufacturing, AEQUILIBRIUM pharma provides a full range of services for bispecific antibody (BsAb) development by leveraging different technological approaches.
With two Fab arms in different epitope binding specificity, bispecific antibodies (BsAbs) are capable of bridging two different molecules (or cells) and thus mediating a recruitment of effector molecules (or cells) and drug delivery systems to targets, so as to improve the selectivity and efficacy of antibody-based treatments for human diseases, especially for oncotherapy. BsAbs consist of various formats, each of which can be crafted via biochemistry and molecular biology methods. Aeqpharma have comprehensive technological approaches and solutions for BsAb development. With the capability to design, optimize different BsAbs and the capacity of manufacturing BsAbs from milligrams to grams scale, we can meet every customer’s requirements.

Leader in plant-derived biologic drug production

Our proprietary  technology platform uses fast-growing plants to produce a wide range of biologic (large molecule) drugs, including monoclonal antibodies and therapeutic proteins. 
See products.
Aequilibrium Pharma is an innovative, proprietary technology platform developed for the expanding field of bispecific antibodies. Based on novel engineering, the platform can expedite the drug development process by 4 weeks and significantly reduce cost-of-goods. The Aeqpharma platform enables almost any mAb sequence pair to be assembled into the bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency (e.g., 2, 3 or 4 binding sites).

Custom Protein Generation
CYP-X production from
gene sequence to crystal
generation for structural analysis
IgM purification to reach 95% purity in SDS-PAGE and HPLC analysis
Kinase-Y production using insect
cell/baculovirus expression system
Developability Assessment
FTE-Model Approach

Recombinant antibody production

I. Generation of coding sequences of the antibody variable domains via synthetic gene design and codon optimization.
II. Expression vector generation by ligation of antibody variable domain synthetic fragments in antibody expression vectors.
III. Transient production of antibody expression vectors .
IV. Purification of the recombinant antibody via affinity chromatography (protein A), ion exchange chromatography and/or and gel filtration chromatography.
V. Optional: Assaying the function of the purified antibody.

Custom protein generation Services

Expression Systems: plant expression system by Geminiviral vectors, which is a DNA replicon system that allows rapid high-yield production of proteins 
Purification Systems: Continuos HPLC, homogenizer, UF/DF & high speed centrifuge includes high-throughput automated purification platform
Protein Characterization:SDS-PAGE/IEF, UV spectrophotometry, SEC-HPLC, SEC-MALS, LC/MS, ITC, X-ray structure, endotoxin detection and other biophysical and biochemical assays
Plant Production Platform: 5 weeks
 

New Letter

Subscribe to our newsletter to discover new molecules and workshops.

Share by: